The U.S. vetoed an application to allow cannabidiol products to be marketed as dietary supplements

On January 2023, 1, the U.S. Food and Drug Administration (FDA) vetoed requests in three petitions from the Consumer Healthcare Products Association (CHPA), the Nutrition Council (CRN), and the Natural Products Association (NPA) asking the FDA to issue regulations allowing cannabidiol (CBD) products as dietary supplements Sale. The petition argues that regulations in this area are necessary to provide an avenue for the legal sale of CBD products as dietary supplements, as U.S. law prohibits the sale of certain pharmaceutical ingredients as dietary supplements. However, the FDA believes that the FDA does not intend to develop regulations in this area because, based on the available scientific evidence, it is unclear how CBD products can meet dietary supplement safety standards. FDA said it does not consider existing dietary supplements and traditional food marketing routes suitable for CBD, and FDA will strike a balance between consumer purchases of CBD products and better management of CBD product risks.